Fig 1.
Flowchart of TNFi use of the 53 AS patients on TNFi for ≥6 years and ≤ 2 different TNFi.
Table 1.
Baseline characteristics of the AS study population treated with TNFi for 6 years (n = 53).
Fig 2.
Disease activity index score ASDAScrp (A), BASDAI (B), levels of acute phase reactant CRP (C), levels of vitamin D (D), BMD (E) and mSASSS progression (F) during 6 years of treatment with TNFi in patients with AS (n = 53). * indicate p-value of <0.05, ** indicate p-value of <0.01 and *** indicate p-value of <0.001 compared to baseline. Horizontal lines represent mean (Fig A, B and D) or median (C, E and F) and dots represent individual values.
Fig 3.
The effect of 6 years of TNFi on markers of bone turnover sCTX (A), OC (B), PINP (C) and BALP (D) in patients with AS (n = 53). * indicate p-value of <0.05, ** indicate p-value of <0.01 and *** indicate p-value of <0.001 compared to baseline. Horizontal lines represent mean and dots represent individual values.
Fig 4.
The net effect of collagen formation and degradation during 6 years of TNFi.
* indicate p-value of <0.05 compared to baseline. Horizontal lines represent mean and dots represent individual values.